Early Apoptotic Cell Injection for Local Osteoarthritis Inflammation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is no effective treatment for osteoarthritis and vanishing bone disease, which are characterized by pain, inflammation, cartilage degeneration, and bone erosion, with existing therapies failing to address these progressive degenerative conditions.

Innovation Solution

Administering a composition of early apoptotic cells or apoptotic supernatant directly into or adjacent to the affected joint or bone tissue to modulate the immune response and reduce inflammation, promote cartilage repair, and inhibit bone erosion.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If systemic administration of apoptotic cells is used to treat autoimmune conditions, then immune homeostasis is restored, but the treatment does not effectively address localized osteoarthritis inflammation and cartilage degeneration

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidroute of administration

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent applies local quality by switching from systemic administration to direct intra-articular injection of apoptotic cells into the affected joint. This localized delivery ensures the therapeutic agent reaches the specific site of cartilage degeneration and inflammation, making the treatment effective for osteoarthritis while maintaining the immune-modulating properties of apoptotic cells.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent uses the synovial fluid and local immune cells within the joint as intermediaries. The directly injected apoptotic cells interact with local macrophages, dendritic cells, and T-cells in the joint environment, triggering anti-inflammatory cytokine release and immune modulation precisely where needed, rather than relying on systemic distribution.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If early apoptotic cells are administered directly into the joint, then local inflammation and cartilage degeneration are reduced, but the complexity of the treatment protocol increases

Engineering Contradiction:

Improvetherapeutic effect on cartilage and boneVSAvoidtreatment protocol complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent extracts the essential therapeutic component (early apoptotic cells) from the complex systemic treatment protocol and delivers it directly to the target site. This simplifies the overall treatment by eliminating the need for systemic distribution mechanisms while concentrating the therapeutic effect where it is most needed, reducing cartilage degeneration and bone erosion.

Inventive Principle:

Principle #2Taking out (Extraction)

3Reliability

If apoptotic cells are used to modulate immune response, then pain and inflammation are reduced, but the mechanism of action is not fully understood for non-autoimmune conditions

Engineering Contradiction:

Improvepain and inflammation reductionVSAvoidunderstanding of mechanism of action

Core Design Contradiction:

ReliabilityVSLoss of information

Solution Approach 1:

The patent leverages the inherent properties of early apoptotic cells to self-modulate the local immune environment. The apoptotic cells naturally express phosphatidylserine on their surface and release anti-inflammatory cytokines, creating an immunosuppressive microenvironment that reduces pain and inflammation without requiring external control or full understanding of all molecular mechanisms.

Inventive Principle:

Principle #25Self-service

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method effectively reduces pain, inflammation, and slows down the degeneration of articular cartilage and bone tissue, improving joint function and quality of life.

Implementation Method 1

direct binding to phosphatidyl serine (PtdSer) and indirect binding to Tyro3, Axl, and Mer (TAM) receptors

Methodology Applied

Scientific EffectPhosphatidyl serine binding:

Implementation Method 2

Multiple mechanisms are used by apoptotic cells to create an immune homeostatic anti-inflammatory state in macrophages and dendritic cells

Methodology Applied

Scientific EffectApoptotic cell-mediated immune suppression:

Implementation Method 3

signaling via opsonins/bridging molecules that use additional integrins and Scavenger Receptors (ScRs) to inhibit Toll-like receptors (TLRs) as well as NF-κb

Methodology Applied

Scientific EffectOpsonin-mediated signaling:

Implementation Method 4

inhibit Toll-like receptors (TLRs) as well as NF-κb, STAT1, and IFN signaling

Methodology Applied

Scientific EffectReceptor inhibition:

Implementation Method 5

activate Liver X Receptors (LXR), Suppression of Cytokine Signaling (SOCS 1/3), Peroxisome Proliferator-Activated Receptors (PPAR)-6

Methodology Applied

Scientific EffectLiver X Receptor activation:

Implementation Method 6

Suppression of Cytokine Signaling (SOCS 1/3)

Methodology Applied

Scientific EffectCytokine signaling suppression:

Data Source

PatentUS20250255901A1Therapeutic apoptotic cells for treatment of osteoarthritis

Publication Date: 2025.08.14 ENLIVEX THERAPEUTICS R&D LTD

AI summary

Methods of use for treating osteoarthritis or vanishing bone disease in a subject in need, including methods of direct administration of a composition of early apoptotic cells or an apoptotic supernatant into or adjacent to the affected joint or bone tissue. Methods of use may reduce pain, swelling, inflammation, bone loss, and or cartilage degeneration, and may increase freedom of movement at an affected joint.